Biosimilar Expansion Organon is expanding its biosimilars portfolio, including PYZCHIVA (ustekinumab) in Canada and an arthritis biosimilar in the U.S. This positions the company as a partner for regional commercialization, supply chain collaboration, and regulatory advisory services across North America.

North America Growth Recent FDA and Health Canada activity demonstrates strong market access potential in the U.S. and Canada for Organon products. This creates openings for channel partnerships, payer engagement programs, and regional distribution arrangements with hospital networks and specialty distributors.

Women’s Health Focus Organon’s portfolio centered on women’s health offers opportunities to engage OB/GYN practices, fertility clinics, and women’s health networks for product adoption, patient education programs, and companion therapies in related conditions where biosimilars may be relevant.

Digital & Data The company uses a modern tech stack including SAP Global Trade Services, Elastic, Power Automate, and other data tools, enabling scalable collaboration, contract management, and pharmacovigilance capabilities. This can support joint go-to-market programs, real-world evidence data sharing, and regulatory compliance services for partners.

Scale & Stability With approximately 5,000 to 10,000 employees and around $10 billion in revenue, Organon represents a stable, well-capitalized partner capable of large-scale manufacturing, global distribution, and long-term supply commitments for biosimilars and established medicines.